Wall Street expects a year-over-year increase in earnings on lower revenues when Nektar Therapeutics (NKTR) reports results for the quarter ended March 2025. While this widely-known consensus ...

On Friday, Jefferies analyst Roger Song upgraded Nektar Therapeutics (NASDAQ:NKTR) stock from Hold to Buy, doubling the price target from $1.00 to $2.00. The decision comes as Nektar prepares to ...

Fintel reports that on April 11, 2025, Jefferies upgraded their outlook for Nektar Therapeutics (BMV:NKTR) from Hold to Buy. There are 549 funds or institutions reporting positions in Nektar ...

Lilly partnered with Nektar on the drug in 2017, paying $150 million upfront with another $250 million at the back end in development and regulatory milestones. It has agreed to fund 75% of the ...

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are the ...

It has been about a month since the last earnings report for Nektar Therapeutics (NKTR). Shares have lost about 38.8% in that time frame, underperforming the S&P 500.

EDWARDSVILLE – Progressive Rock band Nektar comes to The Wildey Theatre, 252 N. Main St., in Edwardsville at 7:30 p.m. Tuesday, April 22. Dubbed the “Mission to Mars” tour, this eagerly ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Nektar Therapeutics before investing. In this article, we go over a few key ...

The result adds nemvaleukin to a growing list of IL-2 candidates that have fallen short in trials, following high-profile disappointments such as Nektar Therapeutics and Bristol Myers Squibb’s ...